ScholarIQanswers from OpenAlex
Vifor Pharma
FunderResearch funding and supported work
Vifor Pharma is a funder indexed in ScholarIQ from OpenAlex.
What is known about Vifor Pharma?
ScholarIQrecord summary
company in Glattbrugg, Switzerland
How many works does Vifor Pharma have?
ScholarIQindexed works
Vifor Pharma has 2,081 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Vifor Pharma?
ScholarIQopenalex
The OpenAlex for Vifor Pharma is on the source record.
What is the ROR of Vifor Pharma?
ScholarIQror
The ROR for Vifor Pharma is on the source record.
What are the most-cited papers on Vifor Pharma?
ScholarIQmost cited works
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Scott D. Solomon, John J.V. McMurray, Inder S. Anand, Junbo Ge, Carolyn S.P. Lam, Aldo P. Maggioni, Felipe A. Martínez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Margaret M. Redfield, Jean L. Rouleau, Dirk J. van Veldhuisen, Faı̈ez Zannad, Michael R. Zile, Akshay S. Desai, Brian Claggett, Pardeep S. Jhund, S. А. Boytsov, Josep Comín‐Colet, John G.F. Cleland, Hans‐Dirk Düngen, Eva Gonçalvesová, Tzvetana Katova, Jose F. Kerr Saraiva, Małgorzata Lelonek, Béla Merkely, Michele Senni, Sanjiv J. Shah, Jingmin Zhou, Adel R. Rizkala, Jianjian Gong, Victor Shi, Martin Lefkowitz
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt, Lars Køber, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So Young Kim, Faı̈ez Zannad
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos, Stefan D. Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P. Maggioni, Piotr Ponikowski, Adriaan A. Voors, Faı̈ez Zannad, So Young Kim, Christina Nowack, Giovanni Palombo, Peter Kolkhof, Nina Kimmeskamp‐Kirschbaum, Alexander Pieper, Bertram Pitt
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
Javed Butler, Stefan D. Anker, Lars H. Lund, Andrew J.S. Coats, Gerasimos Filippatos, Tariq Jamal Siddiqi, Tim Friede, Vincent Fabien, Mikhail Kosiborod, Marco Metra, Ileana L. Piña, Fausto J. Pinto, Patrick Rossignol, Peter van der Meer, Cecilia Bahit, Jan Bělohlávek, Michael Böhm, Jasper J. Brugts, John G.F. Cleland, Justin A. Ezekowitz, Antoni Bayés‐Genís, Israel Gotsman, Assen Goudev, Irakli Khintibidze, JoAnn Lindenfeld, Robert J. Mentz, Béla Merkely, Eliodoro Castro Montes, Wilfried Müllens, José Carlos Nicolau, Aleksandr Parkhomenko, Piotr Ponikowski, Petar Seferović, Michele Senni, Е. V. Shlyakhto, Alain Cohen‐Solal, Peter Szecsödy, Klaus Jensen, Fabio Dorigotti, Matthew R. Weir, Bertram Pitt
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, Rudolf A. de Boer, Kevin Damman, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Mark C. Petrie, Piotr Ponikowski, Marc S. Sabatine, Morten Schou, Scott D. Solomon, Subodh Verma, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, Muthiah Vaduganathan, Pardeep S. Jhund, John J.V. McMurray